HS-10384
Insomnia
Key Facts
About Hansoh Pharma
Hansoh Pharma's mission is to develop and deliver innovative, high-quality medicines that address significant unmet medical needs in China and worldwide. The company has achieved a dominant position as one of China's most valuable pharmaceutical entities, built upon the commercial success of flagship products and a rich pipeline of novel candidates. Its strategy leverages a fully integrated platform from discovery to commercialization, with a sharp focus on oncology and CNS disorders, while actively pursuing strategic global partnerships to expand its international footprint. Hansoh's substantial R&D investment and manufacturing scale underpin its ambition to become a global biopharmaceutical leader.
View full company profileOther Insomnia Drugs
| Drug | Company | Phase |
|---|---|---|
| SILENOR | Currax Pharmaceuticals | Approved |
| CLM-IN01 | Closed Loop Medicine | Pre-commercial (UKCA/CE marked) |
| Levroso Long (Diphenhydramine/Melatonin) | NovaMedica | Approved |
| Insomnia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| CEL-101 (C-122) | Celon Pharma | Phase II |
| CGS-2 | Canopy Growth | Phase II |